{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:38:04Z","timestamp":1791895084881,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40264-020-01031-1","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T03:03:54Z","timestamp":1611025434000},"page":"383-395","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Incidence Rates of Autoimmune Diseases in European Healthcare Databases: A Contribution of the ADVANCE Project"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6310-6019","authenticated-orcid":false,"given":"Corinne","family":"Willame","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Dodd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieke","family":"van der Aa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gino","family":"Picelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne-Dorthe","family":"Emborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnny","family":"Kahlert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Gini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"Huerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Mart\u00edn-Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"McGee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"de Lusignan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Roberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Weibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Titievsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam C. J. M.","family":"Sturkenboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,19]]},"reference":[{"key":"1031_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.07.081","author":"M Sturkenboom","year":"2019","unstructured":"Sturkenboom M, Bahri P, Chiucchiuini A, Grove Krause T, Hahne S, Khromava A, et al. Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines. Vaccine. 2019. https:\/\/doi.org\/10.1016\/j.vaccine.2019.07.081.","journal-title":"Vaccine"},{"key":"1031_CR2","unstructured":"Vaccine monitoring Collaboration for Europe. VAC4EU (2019). Available on:\u00a0https:\/\/vac4eu.org\/. Accessed on 18 Dec 2020."},{"key":"1031_CR3","doi-asserted-by":"crossref","unstructured":"Sturkenboom M, van der Aa L, Bollaerts K, Emborg HD, Ferreira G, Gino R, et al. The ADVANCE distributed network system for evidence generation on vaccines coverage, benefits and risks based on electronic health care data. Vaccine. 2020; Suppl 38:B76\u2013B83.","DOI":"10.1016\/j.vaccine.2019.08.012"},{"key":"1031_CR4","unstructured":"Giesecke J, Kramarz P, Kokki M, for the ADVANCE project team. Blueprint of a framework to rapidly provide scientific evidence on post-marketing vaccination benefits and risks for informed decisions. WP7\u2014Implementability analysis. V2.0. ADVANCE Consortium; 2018. Available on:\u00a0https:\/\/vac4eu.org\/wp-content\/uploads\/2019\/02\/D77Blueprint.pdf. Accessed on 18 Dec 2020."},{"key":"1031_CR5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.micpath.2018.01.004","volume":"116","author":"S Shukla","year":"2018","unstructured":"Shukla S, Singh G, Ahmad S, Pant P. Infections, genetic and environmental factors in pathogenesis of autoimmune thyroid diseases. Microb Pathog. 2018;116:279\u201388.","journal-title":"Microb Pathog"},{"key":"1031_CR6","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1007\/s00018-016-2311-1","volume":"73","author":"S Jorg","year":"2016","unstructured":"Jorg S, Grohme D, Erzler M, Binsfeld M, Haghikia A, Muller D, et al. Environmental factors in autoimmue diseases and their role in multiple sclerosis. Cell Mol Life Sci. 2016;73:4611\u201322.","journal-title":"Cell Mol Life Sci"},{"key":"1031_CR7","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(09)61877-8","volume":"374","author":"S Black","year":"2009","unstructured":"Black S, Eskola J, Siegrist CA, Halsey N, MacDonald N, Law B, et al. Importance of background rates of disease in assessment of vaccine safety during mass immunization with pandemic H1N1 influenza vaccines. Lancet. 2009;374:2115\u201322.","journal-title":"Lancet"},{"key":"1031_CR8","doi-asserted-by":"publisher","first-page":"4378","DOI":"10.1016\/j.vaccine.2011.04.005","volume":"29","author":"X Kurz","year":"2011","unstructured":"Kurz X, Domergue F, Slattery J, Segec A, Szmigiel A, Hidalgo-Simon A. Safety monitoring of influenza A\/H1N1 pandemic vaccines in EudraVigilance. Vaccine. 2011;29:4378\u201387.","journal-title":"Vaccine."},{"key":"1031_CR9","doi-asserted-by":"publisher","first-page":"K98","DOI":"10.1016\/j.vaccine.2013.04.088","volume":"31S","author":"M Baker","year":"2013","unstructured":"Baker M, Nguyen M, Cole D, Lee G, Lieu T. Post-licensure rapid immunization safety monitoring program (PRSIM) data characterization. Vaccine. 2013;31S:K98\u2013112.","journal-title":"Vaccine."},{"key":"1031_CR10","doi-asserted-by":"crossref","unstructured":"Sturkenboom M, Braeye T, van der Aa L, Becker B, Berensci K, Danieli G, et al. ADVANCE database characterization and fit for purpose assessment for multi-country studies on the coverage, benefits and risks for pertussis vaccinations. Vaccine. 2019; 38 Suppl 2:B8\u201321.","DOI":"10.1016\/j.vaccine.2020.01.100"},{"key":"1031_CR11","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/pds.4245","volume":"26","author":"B Becker","year":"2017","unstructured":"Becker B, Avillach P, Romio S, van Mulligen E, Weibel D, Sturkenboom M, Kors J, for the ADVANCE consortium. CodeMapper: semiautomatic coding of case definitions. A contribution from the ADVANCE project. Pharmacoepidemiol Drug Saf. 2017;26:998\u20131005.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1031_CR12","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jaut.2016.03.003","volume":"69","author":"J Ji","year":"2016","unstructured":"Ji J, Sundquist J, Sundquist K. Gender-specific incidence of autoimmune diseases from national registers. J Autoimmun. 2016;69:102\u20136.","journal-title":"J Autoimmun"},{"key":"1031_CR13","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00415-014-7266-2","volume":"261","author":"E Martinez-Lapiscina","year":"2014","unstructured":"Martinez-Lapiscina E, Fraga-Pumar E, Pastor X, Gomez M, Conesa A, Lozano-Rubi R, et al. Is the incidence of optic neuritis rising? Evidence from an epidemiological study in Barcelona (Spain), 2008\u20132012. J Neurol. 2014;261:759\u201367.","journal-title":"J Neurol."},{"key":"1031_CR14","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.vaccine.2012.12.015","volume":"31","author":"L Wijnans","year":"2013","unstructured":"Wijnans L, Lecomte C, de Vries C, Weibel D, Sammon C, Hviid A, et al. The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine. 2013;31:1246\u201354.","journal-title":"Vaccine."},{"key":"1031_CR15","first-page":"17","volume":"19","author":"D O\u2019Flanagran","year":"2014","unstructured":"O\u2019Flanagran D, Barret AS, Foley M, Cotter S, Bonner C, Crowe C, et al. Investigation of an association between onset of narcolepsy and vaccination with pandemic influenza vaccine, Ireland April 2009-December 2010. Euro Surveill. 2014;19:17.","journal-title":"Euro Surveill."},{"issue":"13","key":"1031_CR16","doi-asserted-by":"publisher","first-page":"e0204799","DOI":"10.1371\/journal.pone.0204799","volume":"10","author":"C Dodd","year":"2018","unstructured":"Dodd C, de Ridder M, Huang WT, Weibel D, Giner-Soriano M, Perez-Vilar S, et al. Incidence rates of narcolepsy diagnoses in Taiwan, Canada, and Europe: the use of statistical simulation to evaluate methods for the rapid assessment of potential safety issues on a population level in the SOMNIA study. PLoS ONE. 2018;10(13):e0204799.","journal-title":"PLoS ONE"},{"issue":"645","key":"1031_CR17","doi-asserted-by":"publisher","first-page":"e271","DOI":"10.3399\/bjgp16X684325","volume":"66","author":"G Hall","year":"2016","unstructured":"Hall G, Tulloh L, Tilloh R. Kawasaki disease incidence in children and adolescents: an observational study in primary care. Br J Gen Pract. 2016;66(645):e271.","journal-title":"Br J Gen Pract"},{"key":"1031_CR18","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s00431-017-2947-3","volume":"176","author":"R Cimaz","year":"2017","unstructured":"Cimaz R, Fanti E, Mauro A, Voller F, Rusconi F. Epidemiology of Kawasaki disease in Italy: surveillance from national hospitalization records. Eur J Pediatr. 2017;176:1061\u20135.","journal-title":"Eur J Pediatr"},{"key":"1031_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.07.045","author":"R Gini","year":"2019","unstructured":"Gini R, Dodd CN, Bollaerts K, Bartolini C, Roberto G, Huerta-Alvarez C, et al. Quantifying outcome misclassification in multi-database studies: the case study of pertussis in the ADVANCE project. Vaccine. 2019. https:\/\/doi.org\/10.1016\/j.vaccine.2019.07.045.","journal-title":"Vaccine"},{"issue":"2","key":"1031_CR20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/pds.3918","volume":"25","author":"O Mahaux","year":"2016","unstructured":"Mahaux O, Bauchau V, Van Holle L. Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines. Pharmacoepidemiol Drug Saf. 2016;25(2):215\u201322.","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"7","key":"1031_CR21","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/pds.4419","volume":"27","author":"S Mac Donald","year":"2018","unstructured":"Mac Donald S, Nijsten D, Bollaerts K, Bauwens J, Praet N, van der Sande M, et al. Methodology for computing the burden of disease of adverse events following immunization. Pharmacoepidemiol Drug Saf. 2018;27(7):724\u201330.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1031_CR22","doi-asserted-by":"publisher","first-page":"7205","DOI":"10.1016\/j.vaccine.2012.10.017","volume":"30","author":"A Van Hoek","year":"2012","unstructured":"Van Hoek A, Choi YH, Trotter C, Miller E, Jit M. The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England. Vaccine. 2012;30:7205\u201313.","journal-title":"Vaccine"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-01031-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-020-01031-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-01031-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T15:08:41Z","timestamp":1685200121000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-020-01031-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,19]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["1031"],"URL":"https:\/\/doi.org\/10.1007\/s40264-020-01031-1","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,19]]},"assertion":[{"value":"2 December 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Innovative Medicines Initiative Joint Undertaking funded this project under ADVANCE Grant agreement number 115557, resources of which were composed of a financial contribution from the European Union\u2019s Seventh Framework Programme (FP7\/2007\u20132013) and in kind contributions from European Federation of Pharmaceutical Industries and Associations (EFPIA) member companies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"At the time of the study and manuscript development, Corinne Willame worked part time with the GlaxoSmithKline (GSK) group of companies and declares not to receive any financial support from the GSK group of companies for the submitted work. At the time of the study and manuscript development, Lina Titievsky was a Pfizer employee. Rosa Gini is employed by ARS, a public health agency that conducts or participates in pharmacoepidemiology studies. The budget of ARS is partially sustained by such studies. Simon de Lusignan has been a member of Advisory Boards for Sanofi and Seqirus, and has received funding for vaccine-related researches from GSK, Seqirus, and Takeda. Daniel Weibel has been a consultant for GSK\u2019s malaria vaccine program. Miriam Sturkenboom is principal investigator of post-authorization safety studies requested by the European Medicines Agency, for Novartis, none of which were related to the topic described. Caitlin Dodd, Lieke van der Aa, Gino Picelli, Hanne-Dorthe Emborg, Johnny Kahlert, Consuelo Huerta, Elisa Mart\u00edn-Merino, Chris McGee, Giuseppe Roberto, and Marco Villa declare they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this type of study, governance approval is mandatory to access data sources.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Data are available from the DAPs of each of the participating data sources for researchers who meet the criteria to access confidential data. The minimal underlying dataset for replication would require interested researchers to contact each individual listed for access to their data.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"All authors contributed equally to the work submitted.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}}]}}